ELI LILLY AND COMPANY (NYSE: LLY)

ELI LILLY AND COMPANY

NYSE: LLY (Eli Lilly and Company)

最近更新时间: 5天之前, 1:00PM

795.35

7.16 (0.91%)

加入群组

前收盘价格	788.19
收盘价格	791.33
成交量	2,055,067
平均成交量 (3个月)	3,599,157
市值	715,270,914,048

市盈率 (P/E TTM)	85.52
预期市盈率 (P/E Forward)	35.09
价格/销量 (P/S)	17.60
股市价格/股市净资产 (P/B)	50.23

52周波幅	561.65 (-29%) — 972.53 (22%)
利润日期	4 Feb 2025 - 10 Feb 2025
股息率 (DY TTM)	0.65%

市场趋势

		短期	中期
行业	Drug Manufacturers - General (US)	混合的	看涨
	Drug Manufacturers - General (全球的)	混合的	看涨
股票	Eli Lilly and Company	看跌	看涨

AIStockmoo 评分

0.2

分析师共识	2.0
内部交易活动	1.5
价格波动	2.0
技术平均移动指标	-2.5
技术振荡指标	-2.0
平均	0.20

相关股票

股票	市值	DY	P/E（TTM）	P/B
LLY	715 B	0.65%	85.52	50.23
NVS	217 B	3.57%	18.61	4.88
JNJ	362 B	3.26%	24.87	5.23
ABBV	360 B	3.09%	70.84	51.84
MRK	251 B	3.11%	20.75	5.72
PFE	143 B	6.66%	33.64	1.57

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
部门	Healthcare
行业	Drug Manufacturers - General
投资方式	Large Growth
内部持股比例	0.15%
机构持股比例	83.38%

所有权

姓名	日期	持有股份
Lilly Endowment Inc	30 Sep 2024	96,891,978
Pnc Financial Services Group, Inc.	30 Sep 2024	51,360,730

52周波幅	561.65 (-29%) — 972.53 (22%)
目标价格波幅	885.00 (11%) — 1,250.00 (-99%)
高	1,250.00 (Citigroup, 57.16%)	购买
中	1,033.00 (29.88%)
低	885.00 (Cantor Fitzgerald, 11.27%)	购买
平均值	1,050.89 (32.13%)
总计	9 购买
平均价格@调整类型	864.40

公司	日期	目标价格	调整类型	价格@调整类型
Wolfe Research	15 Nov 2024	1,000.00 (25.73%)	购买	746.20
Deutsche Bank	04 Nov 2024	1,015.00 (27.62%)	购买	806.14
Deutsche Bank	03 Oct 2024	1,025.00 (28.87%)	购买	885.55
B of A Securities	31 Oct 2024	1,100.00 (38.30%)	购买	829.74
Barclays	31 Oct 2024	975.00 (22.59%)	购买	829.74
Citigroup	25 Oct 2024	1,250.00 (57.16%)	购买	892.70
Citigroup	13 Sep 2024	1,060.00 (33.27%)	购买	923.71
Bernstein	17 Oct 2024	1,100.00 (38.30%)	购买	917.12
Truist Securities	10 Oct 2024	1,033.00 (29.88%)	购买	910.69
Cantor Fitzgerald	16 Sep 2024	885.00 (11.27%)	购买	923.54
Cantor Fitzgerald	09 Sep 2024	885.00 (11.27%)	购买	908.27
JP Morgan	13 Sep 2024	1,100.00 (38.30%)	购买	923.71
显示更多

该时间范围内无数据。

日期	类型	细节
04 Dec 2024	CNBC	Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
04 Dec 2024	公告	Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
26 Nov 2024	CNBC	Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
19 Nov 2024	公告	Lilly announces changes on board of directors
18 Nov 2024	公告	Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
16 Nov 2024	公告	Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity
13 Nov 2024	公告	Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks
13 Nov 2024	CNBC	Amgen says no concerns around weight loss drug’s bone density data after stock falls
05 Nov 2024	公告	Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
01 Nov 2024	公告	Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium
30 Oct 2024	CNBC	Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
30 Oct 2024	CNBC	Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
30 Oct 2024	CNBC	Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
30 Oct 2024	公告	Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products
29 Oct 2024	公告	Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study
28 Oct 2024	公告	Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease
28 Oct 2024	公告	Lilly declares fourth-quarter 2024 dividend
25 Oct 2024	公告	Lilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab
23 Oct 2024	公告	Lilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E Ε4 Heterozygotes or Non-Carriers
23 Oct 2024	CNBC	Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
16 Oct 2024	公告	Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies
16 Oct 2024	公告	Lilly confirms date and conference call for third-quarter 2024 financial results announcement
14 Oct 2024	公告	Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
02 Oct 2024	公告	Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials
02 Oct 2024	CNBC	Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
25 Sep 2024	CNBC	Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
25 Sep 2024	公告	New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis
24 Sep 2024	公告	Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease
24 Sep 2024	CNBC	'Stop ripping us off': Senate grills Novo Nordisk CEO on weight loss drug pricing
21 Sep 2024	CNBC	FTC sues drug middlemen for allegedly inflating insulin prices
16 Sep 2024	CNBC	Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
13 Sep 2024	公告	FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
12 Sep 2024	公告	Lilly expands manufacturing footprint in Ireland with $1.8 billion investment
10 Sep 2024	公告	Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes
10 Sep 2024	公告	With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes
09 Sep 2024	公告	Lilly appoints Lucas Montarce as executive vice president and chief financial officer
05 Sep 2024	公告	In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin
05 Sep 2024	TheFinance	3 US Blue-Chip Earnings Reports That You Should Not Miss
04 Sep 2024	公告	Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries
显示更多

股息率 (DY TTM)	0.65%
5年平均股息收益率	1.36%
股息支付比率	54.20%
预计下次股息支付	Sep 2025

除息日	公告日期	支付日期	详情
15 Nov 2024	28 Oct 2024	10 Dec 2024	1.3 现金
15 Aug 2024	24 Jun 2024	10 Sep 2024	1.3 现金
15 May 2024	06 May 2024	10 Jun 2024	1.3 现金
14 Feb 2024	08 Dec 2023	08 Mar 2024	1.3 现金
14 Nov 2023	01 Nov 2023	08 Dec 2023	1.13 现金
14 Aug 2023	26 Jun 2023	08 Sep 2023	1.13 现金
12 May 2023	01 May 2023	09 Jun 2023	1.13 现金
14 Feb 2023	12 Dec 2022	10 Mar 2023	1.13 现金
14 Nov 2022	17 Oct 2022	09 Dec 2022	0.98 现金
12 Aug 2022	27 Jun 2022	09 Sep 2022	0.98 现金
13 May 2022	02 May 2022	10 Jun 2022	0.98 现金
14 Feb 2022	13 Dec 2021	10 Mar 2022	0.98 现金
12 Nov 2021	18 Oct 2021	10 Dec 2021	0.85 现金
12 Aug 2021	29 Jun 2021	10 Sep 2021	0.85 现金
13 May 2021	03 May 2021	10 Jun 2021	0.85 现金
11 Feb 2021	14 Dec 2020	10 Mar 2021	0.85 现金
12 Nov 2020	19 Oct 2020	10 Dec 2020	0.74 现金
13 Aug 2020	15 Jul 2020	10 Sep 2020	0.74 现金
14 May 2020	04 May 2020	10 Jun 2020	0.74 现金
13 Feb 2020	16 Dec 2019	10 Mar 2020	0.74 现金
14 Nov 2019	22 Oct 2019	10 Dec 2019	0.645 现金
14 Aug 2019	20 Jun 2019	10 Sep 2019	0.645 现金
16 May 2019	07 May 2019	10 Jun 2019	0.645 现金
14 Feb 2019	19 Dec 2018	08 Mar 2019	0.645 现金
14 Nov 2018	16 Oct 2018	10 Dec 2018	0.5625 现金
14 Aug 2018	19 Jun 2018	10 Sep 2018	0.5625 现金
16 May 2018	07 May 2018	08 Jun 2018	0.5625 现金
14 Feb 2018	11 Dec 2017	09 Mar 2018	0.5625 现金
14 Nov 2017	16 Oct 2017	08 Dec 2017	0.52 现金
11 Aug 2017	19 Jun 2017	08 Sep 2017	0.52 现金
11 May 2017	01 May 2017	09 Jun 2017	0.52 现金
13 Feb 2017	12 Dec 2016	10 Mar 2017	0.52 现金
10 Nov 2016	17 Oct 2016	09 Dec 2016	0.51 现金
11 Aug 2016	20 Jun 2016	09 Sep 2016	0.51 现金
11 May 2016	02 May 2016	10 Jun 2016	0.51 现金
10 Feb 2016	08 Dec 2015	10 Mar 2016	0.51 现金
10 Nov 2015	19 Oct 2015	10 Dec 2015	0.5 现金
12 Aug 2015	15 Jun 2015	10 Sep 2015	0.5 现金
14 May 2015	04 May 2015	10 Jun 2015	0.5 现金
11 Feb 2015	15 Dec 2014	10 Mar 2015	0.5 现金
12 Nov 2014	20 Oct 2014	10 Dec 2014	0.49 现金
13 Aug 2014	16 Jun 2014	10 Sep 2014	0.49 现金
13 May 2014	05 May 2014	10 Jun 2014	0.49 现金
12 Feb 2014	16 Dec 2013	10 Mar 2014	0.49 现金
13 Nov 2013	21 Oct 2013	10 Dec 2013	0.49 现金
13 Aug 2013	18 Jun 2013	10 Sep 2013	0.49 现金
14 May 2013	03 May 2013	10 Jun 2013	0.49 现金
13 Feb 2013	17 Dec 2012	08 Mar 2013	0.49 现金
13 Nov 2012	15 Oct 2012	10 Dec 2012	0.49 现金
13 Aug 2012	19 Jun 2012	10 Sep 2012	0.49 现金
13 Feb 2012	12 Dec 2011	09 Mar 2012	0.49 现金
10 Nov 2011	17 Oct 2011	09 Dec 2011	0.49 现金
11 Aug 2011	20 Jun 2011	09 Sep 2011	0.49 现金
11 May 2011	18 Apr 2011	10 Jun 2011	0.49 现金
11 Feb 2011	13 Dec 2010	10 Mar 2011	0.49 现金
10 Nov 2010	18 Oct 2010	10 Dec 2010	0.49 现金
11 Aug 2010	21 Jun 2010	10 Sep 2010	0.49 现金
12 May 2010	19 Apr 2010	10 Jun 2010	0.49 现金
10 Feb 2010	14 Dec 2009	10 Mar 2010	0.49 现金
10 Nov 2009	19 Oct 2009	10 Dec 2009	0.49 现金
12 Aug 2009	22 Jun 2009	10 Sep 2009	0.49 现金
13 May 2009	20 Apr 2009	10 Jun 2009	0.49 现金
11 Feb 2009	15 Dec 2008	10 Mar 2009	0.49 现金
12 Nov 2008	20 Oct 2008	10 Dec 2008	0.47 现金
13 Aug 2008	20 Jun 2008	10 Sep 2008	0.47 现金
13 Feb 2008	17 Dec 2007	10 Mar 2008	0.47 现金
13 Nov 2007	15 Oct 2007	10 Dec 2007	0.425 现金
13 Aug 2007	21 Jun 2007	10 Sep 2007	0.425 现金
11 May 2007	16 Apr 2007	08 Jun 2007	0.425 现金
13 Feb 2007	18 Dec 2006	09 Mar 2007	0.425 现金
13 Nov 2006	16 Oct 2006	08 Dec 2006	0.4 现金
11 Aug 2006	26 Jun 2006	08 Sep 2006	0.4 现金
11 May 2006	24 Apr 2006	09 Jun 2006	0.4 现金
13 Feb 2006	19 Dec 2005	10 Mar 2006	0.4 现金
10 Nov 2005	17 Oct 2005	09 Dec 2005	0.38 现金
11 Aug 2005	24 Jun 2005	09 Sep 2005	0.38 现金
11 May 2005	18 Apr 2005	10 Jun 2005	0.38 现金
11 Feb 2005	20 Dec 2004	10 Mar 2005	0.38 现金
10 Nov 2004	18 Oct 2004	10 Dec 2004	0.355 现金
11 Aug 2004	28 Jun 2004	10 Sep 2004	0.355 现金
12 May 2004	19 Apr 2004	10 Jun 2004	0.355 现金
11 Feb 2004	15 Dec 2003	10 Mar 2004	0.355 现金
12 Nov 2003	20 Oct 2003	10 Dec 2003	0.335 现金
13 Aug 2003	23 Jun 2003	10 Sep 2003	0.335 现金
13 May 2003	28 Apr 2003	10 Jun 2003	0.335 现金
12 Feb 2003	16 Dec 2002	10 Mar 2003	0.335 现金
13 Nov 2002	21 Oct 2002	10 Dec 2002	0.31 现金
13 Aug 2002	24 Jun 2002	10 Sep 2002	0.31 现金
13 May 2002	15 Apr 2002	10 Jun 2002	0.31 现金
13 Feb 2002	17 Dec 2001	08 Mar 2002	0.31 现金
13 Nov 2001	15 Oct 2001	10 Dec 2001	0.28 现金
13 Aug 2001	25 Jun 2001	10 Sep 2001	0.28 现金
11 May 2001	16 Apr 2001	11 Jun 2001	0.28 现金
13 Feb 2001	18 Dec 2000	09 Mar 2001	0.28 现金
13 Nov 2000	16 Oct 2000	11 Dec 2000	0.26 现金
11 Aug 2000	26 Jun 2000	11 Sep 2000	0.26 现金
11 May 2000	17 Apr 2000	09 Jun 2000	0.26 现金
11 Feb 2000	20 Dec 1999	10 Mar 2000	0.26 现金
10 Nov 1999	18 Oct 1999	10 Dec 1999	0.23 现金
11 Aug 1999	19 Jul 1999	10 Sep 1999	0.23 现金
12 May 1999	19 Apr 1999	10 Jun 1999	0.23 现金
10 Feb 1999	21 Dec 1998	10 Mar 1999	0.23 现金
10 Nov 1998	20 Oct 1998	10 Dec 1998	0.2 现金
12 Aug 1998	20 Jul 1998	10 Sep 1998	0.2 现金
13 May 1998	20 Apr 1998	10 Jun 1998	0.2 现金
11 Feb 1998	15 Dec 1997	10 Mar 1998	0.2 现金
12 Nov 1997	15 Sep 1997	10 Dec 1997	0.2 现金
13 Aug 1997	21 Jul 1997	10 Sep 1997	0.36 现金
13 May 1997	21 Apr 1997	10 Jun 1997	0.36 现金
12 Feb 1997	16 Dec 1996	10 Mar 1997	0.36 现金
13 Nov 1996	21 Oct 1996	10 Dec 1996	0.3425 现金
13 Aug 1996	15 Jul 1996	10 Sep 1996	0.3425 现金
13 May 1996	15 Apr 1996	10 Jun 1996	0.3425 现金
13 Feb 1996	18 Dec 1995	11 Mar 1996	0.3425 现金
13 Nov 1995	17 Oct 1995	11 Dec 1995	0.685 现金
11 Aug 1995	17 Jul 1995	11 Sep 1995	0.645 现金
09 May 1995	17 Apr 1995	12 Jun 1995	0.645 现金
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2024	5.20	4	0.65
2023	4.52	4	0.78
2022	3.92	4	1.07
2021	3.40	4	1.23
2020	2.96	4	1.75
2019	2.58	4	1.96
2018	2.25	4	1.94
2017	2.08	4	2.46
2016	2.04	4	2.77
2015	2.00	4	2.37
2014	1.96	4	2.84
2013	1.96	4	3.84
2012	1.47	3	2.98
2011	1.96	4	4.72
2010	1.96	4	5.59
2009	1.96	4	5.49
2008	1.41	3	3.50
2007	1.70	4	3.18
2006	1.60	4	3.07
2005	1.52	4	2.69
2004	1.42	4	2.50
2003	1.34	4	1.91
2002	1.24	4	1.95
2001	1.12	4	1.43
2000	1.04	4	1.12
1999	0.920	4	1.38
1998	0.800	4	0.90
1997	1.28	4	1.84
1996	1.37	4	3.75
1995	1.98	3	7.02
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2024	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	20.48%
营业利益率 (TTM)	39.77%
稀释每股收益 (EPS TTM)	9.31
季度收入增长率 (YOY)	20.40%
季度盈利增长率 (YOY)	68.30%

总债务/股东权益 (D/E MRQ)	218.08%
流动比率 (MRQ)	1.27
营业现金流 (OCF TTM)	6.03 B
杠杆自由现金流 (LFCF TTM)	-1.31 B

资产报酬率 (ROA TTM)	13.95%
股东权益报酬率 (ROE TTM)	65.32%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)